用于口服的XA因子抑制剂相关的脑内出血的前素复合缩物
Mohammad Shamiea1, Hassan Sbehi2, Nadim Abu Rashed3
1Department of Medicine A, Meir Medical Center, Tel Aviv, Israel.
Research and practice in thrombosis and haemostasis
|February 16, 2026
概括
四因子前激素复合物缩剂 (4F-PCC) 有效地逆转了与XA抑制剂相关的脑内出血 (ICH),并具有较低的血栓形成风险. 这项研究支持4F-PCC用于FXaI-ICH,与其他逆转剂相比显示出有利的结果.
科学领域:
- 神经学 神经学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与Xa因子抑制剂 (FXaI) 相关的脑内出血 (ICH) 需要快速逆转抗凝.
- 安德克萨内特阿尔法,一种特定的FXaI解药,显示出有效性,但携带高血栓栓塞的风险.
- 经常使用四因子前激素复合缩物 (4F-PCC),但实际数据有限.
研究的目的:
- 评估4F-PCC在逆转FXaI相关的ICH中的静血效果.
- 评估4F-PCC在该患者群体中的安全概况,包括血栓栓塞事件和死亡率.
主要方法:
- 一个单一中心的回顾性观察研究包括与FXaI相关的ICH患者,这些患者接受了4F-PCC治疗.
- 主要终点:由血液瘤扩张定义的静血疗效,NIHSS得分变化和没有救援疗法 (ANNEXA-I标准).
- 二级终点:48小时后神经状况稳定;安全结果包括30天的血栓栓塞事件和死亡率.
主要成果:
- 在52名患者中,75.0%的患者达到主终点.
- 在48小时后,在71.2%的患者中观察到稳定的神经状态.
- 发血栓栓塞事件的发生率较低 (1.9%),30天死亡率为23.1%.
结论:
- 4F-PCC在FXaI相关的ICH中显示出高血静效和低血栓栓塞风险.
- 结果支持在FXaI-ICH管理的临床指南中使用4F-PCC.
- 低的血栓事件率与其他逆转药物形成了有利的对比.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Venous Thrombosis III: Interprofessional Care
383
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
383
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Extrinsic and Intrinsic Pathways of Hemostasis
13.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
13.4K
Coagulation
10.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
10.8K
Clot Retraction and Fibrinolysis
9.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.2K


